The Motley Fool
19 Jul 2026, 00:16 UTC · 6h ago
IHE vs IXJ: Which Popular Healthcare ETF Is the Better Buy for Investors?
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
The Motley Fool
19 Jul 2026, 00:16 UTC · 6h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
The iShares U.S. Pharmaceuticals ETF (IHE) is highly concentrated, with Eli Lilly and Johnson & Johnson together comprising over 43% of the portfolio. — Extreme concentration in two names increases idiosyncratic risk and vulnerability to stock-specific shocks.
-0.30IHE's recent outperformance is largely attributed to the success of GLP-1 weight-loss drugs. — Highlights the primary growth driver for the fund but also signals a reliance on a specific drug class.
+0.20The iShares Global Healthcare ETF (IXJ) provides broader diversification across geography and sub-sectors, including medical devices and healthcare services. — Diversification typically lowers volatility and risk, though it may temper explosive growth compared to concentrated funds.
+0.10Continue reading
6 related stories
Top 3 movers · tap to explore
IXJ possesses significantly higher liquidity with $4.1 billion in AUM compared to IHE's $1.4 billion. — Higher liquidity reduces slippage for large institutional trades but is a marginal factor for retail investors.
+0.05Which stocks this story touches
Mentioned as a top holding whose success with weight-loss drugs has driven gains for related ETFs.
Highlighted as a core, diversified holding across multiple healthcare ETFs.
Listed as a top position in the IHE ETF without specific qualitative analysis.
Listed as a top position in the IXJ ETF without specific qualitative analysis.
[mutual] Both companies operate as primary pharmaceutical manufacturers in the U.S. market.
[mutual] Both are top holdings within the U.S. pharmaceutical industry and compete for the same customer base.
[mutual] Both are primary holdings in the pharmaceutical sector and compete for market share in healthcare.
[mutual] Both are major healthcare holdings and compete within the global pharmaceutical and medical markets.
[mutual] Both companies are major pharmaceutical holdings in healthcare ETFs and compete in the drug manufacturing market, specifically regarding GLP-1 treatments and biosimilars.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
The Motley Fool
15h ago
